Isolation and transplantation of autologous peripheral CD34+ progenitor cells highly purified by magnetic-activated cell sorting

被引:108
作者
Handgretinger, R
Lang, P
Schumm, M
Taylor, G
Neu, S
Koscielnak, E
Niethammer, D
Klingebiel, T
机构
[1] Univ Tubingen, Childrens Hosp, D-72070 Tubingen, Germany
[2] Olgahosp Stuttgart, Stuttgart, Germany
关键词
CD34; isolation; MACS; high-dose chemotherapy;
D O I
10.1038/sj.bmt.1701228
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Peripheral stem cells were mobilized and collected in 26 pediatric patients with malignant diseases. A total of 47 leukaphereses were performed in the 26 patients. The mean number of nucleated cells collected was 4.5 +/- 2.6 x 10(8)/kg and the number of CD34(+) progenitors collected was 6.7 +/- 6.8 x 10(6)/kg. CD34-positive selection was performed using a two-step method of magnetic-activated cell sorting (MACS) in 24 patients or a combination of an immunoaffinity column and MACS in two patients. The purity of the positively selected CD34(+) progenitors was 98.8 +/- 0.7% and the number of isolated CD34(+) cells was 6.5 +/- 5.9 x 10(6)/kg. Thus, the mean recovery of CD34(+) cells was 93 +/- 10%. In 22 of the 26 patients, high-dose chemotherapy was performed with subsequent reinfusion of the highly purified CD34(+) cells. In all 22 patients, a normal hematopoietic reconstitution was seen with a mean time of 12.4 +/- 2.7 days to reach >0.5 x 10(9)/I neutrophils (range 8-19 days). The time to reach independence from platelet transfusion was 31.6 +/- 17.0 days (range 16-78 days). There were no transplant-related deaths. In summary, we have shown that mobilized peripheral CD34(+) progenitors can be highly purified with a good recovery and that reinfusion of these cells after high-dose chemotherapy results in a rapid, complete and sustained engraftment. We conclude that this method can be used for purging in any CD34-negative malignancies and for autologous T and B cell depletion in the treatment of autoimmune diseases with high-dose immunoablative therapy.
引用
收藏
页码:987 / 993
页数:7
相关论文
共 28 条
[1]  
BERENSON RJ, 1991, BLOOD, V77, P1717
[2]  
Brenner M K, 1994, J Hematother, V3, P33, DOI 10.1089/scd.1.1994.3.33
[3]   GENE-MARKING TO TRACE ORIGIN OF RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
BRENNER, MK ;
RILL, DR ;
MOEN, RC ;
KRANCE, RA ;
MIRRO, J ;
ANDERSON, WF ;
IHLE, JN .
LANCET, 1993, 341 (8837) :85-86
[4]  
BRUGGER W, 1994, BLOOD, V83, P636
[5]  
BURT RK, 1995, BONE MARROW TRANSPL, V16, P1
[6]   COMPARISON OF PURITY AND ENRICHMENT OF CD34(+) CELLS FROM BONE-MARROW, UMBILICAL-CORD AND PERIPHERAL-BLOOD (PRIMED FOR APHERESIS) USING 5 SEPARATION SYSTEMS [J].
DEWYNTER, EA ;
COUTINHO, LH ;
PEI, X ;
MARSH, JCW ;
HOWS, J ;
LUFT, T ;
TESTA, NG .
STEM CELLS, 1995, 13 (05) :524-532
[7]  
GALE RP, 1992, BONE MARROW TRANSPL, V9, P151
[8]   Positive selection and transplantation of peripheral CD34+ progenitor cells: Feasibility and purging efficacy in pediatric patients with neuroblastoma [J].
Handgretinger, R ;
Greil, J ;
Schurmann, U ;
Lang, P ;
GonzalezRamella, O ;
Schmidt, I ;
Fuhrer, R ;
Niethammer, D ;
Klingebiel, T .
JOURNAL OF HEMATOTHERAPY, 1997, 6 (03) :235-242
[9]  
HANDGRETINGER R, 1992, CANCER RES THER CONT, V3, P43
[10]   A PHASE-I STUDY OF HUMAN MOUSE CHIMERIC ANTIGANGLIOSIDE GD2 ANTIBODY CH14.18 IN PATIENTS WITH NEUROBLASTOMA [J].
HANDGRETINGER, R ;
ANDERSON, K ;
LANG, P ;
DOPFER, R ;
KLINGEBIEL, T ;
SCHRAPPE, M ;
REULAND, P ;
GILLIES, SD ;
REISFELD, RA ;
NIETHAMMER, D .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (02) :261-267